Increased Persistency in Medication Use by US Medicare Beneficiaries With Diabetes Is Associated With Lower Hospitalization Rates and Cost Savings

被引:43
作者
Stuart, Bruce C. [1 ]
Simoni-Wastila, Linda [1 ]
Zhao, Lirong [1 ]
Lloyd, Jennifer T. [1 ]
Doshi, Jalpa A. [2 ]
机构
[1] Univ Maryland, Peter Lamy Ctr Drug Therapy & Aging, Baltimore, MD 21201 USA
[2] Univ Penn, Dept Gen Internal Med, Philadelphia, PA 19104 USA
关键词
ADHERENCE;
D O I
10.2337/dc08-1311
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess the relationship between annual fills for antidiabetes medications, ACE inhibitors, angiotensin II receptor blockers (ARBs), and lipid-lowering agents on hospitalization and Medicare spending for beneficiaries with diabetes. RESEARCH DESIGN AND METHODS - Using Medicare Current Beneficiary Survey data from 1997 to 2004, we identified 7,441 community-dwelling beneficiaries with diabetes, who contributed 14,317 person-years of data for the analysis. We used multivariate regression analysis to estimate the effect of persistency in medication fills on hospitalization risk, hospital days, and Medicare spending. RESULTS - For users of older oral antidiabetes agents, ACE inhibitors, ARBs, and statins, each additional prescription fill was associated with significantly lower risk of hospitalization, fewer hospital days, and lower Medicare spending. CONCLUSIONS - These results suggest an economic case for promoting greater persistency in use of drugs with approved indications by Medicare beneficiaries with diabetes, however, additional research is needed to corroborate the study's cross-sectional findings.
引用
收藏
页码:647 / 649
页数:3
相关论文
共 15 条
  • [1] Standards of medical care in diabetes 2008
    不详
    [J]. DIABETES CARE, 2008, 31 : S12 - S54
  • [2] Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures
    Buntin, MB
    Zaslavsky, AM
    [J]. JOURNAL OF HEALTH ECONOMICS, 2004, 23 (03) : 525 - 542
  • [3] *CTR MED MED SERV, 2006, MED PREM DED 2006
  • [4] Predictors of health care costs in adults with diabetes
    Gilmer, TP
    O'Connor, PJ
    Rush, WA
    Crain, AL
    Whitebird, RR
    Hanson, AM
    Solberg, LI
    [J]. DIABETES CARE, 2005, 28 (01) : 59 - 64
  • [5] Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607
  • [6] Unintended consequences of caps on medicare drug benefits
    Hsu, John
    Price, Mary
    Huang, Jie
    Brand, Richard
    Fung, Vicki
    Hui, Rita
    Fireman, Bruce
    Newhouse, Joseph P.
    Selby, Joseph V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22) : 2349 - 2359
  • [7] Lawrence DB, 2006, J MANAGE CARE PHARM, V12, P466
  • [8] Petersen M, 2003, DIABETES CARE, V26, P917
  • [9] Economic costs of diabetes in the US in 2007
    Petersen, Matt
    [J]. DIABETES CARE, 2008, 31 (03) : 596 - 615
  • [10] Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes
    Rosen, AB
    Hamel, MB
    Weinstein, MC
    Cutler, DM
    Fendrick, AM
    Vijan, S
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (02) : 89 - 99